Residual vessel length on magnetic resonance angiography identifies poor responders to alteplase in acute middle cerebral artery occlusion patients: Exploratory analysis of the Japan Alteplase Clinical Trial II

Stroke

Volumn 41, Issue 12, 2010, Pages 2828-2833

  Hirano, Teruyuki ^a   Sasaki, Makoto ^b   Mori, Etsuro ^c   Minematsu, Kazuo ^d   Nakagawara, Jyoji ^e   Yamaguchi, Takenori ^d  

^a KUMAMOTO UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^e Nakamura Memorial Hospital   (Japan)

Author keywords

acute ischemic stroke; magnetic resonance angiography; middle cerebral artery occlusion; recanalization; tissue plasminogen activator

Indexed keywords

ALTEPLASE;

AGED; ARTERY DIAMETER; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; EXPLORATORY RESEARCH; FEMALE; HUMAN; JAPANESE; LOGISTIC REGRESSION ANALYSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANKIN SCALE; RECANALIZATION; RECEIVER OPERATING CHARACTERISTIC;

AGE FACTORS; AGED; BLOOD VESSELS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENOUS; JAPAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; PLASMINOGEN ACTIVATORS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SEX FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 78650416584     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.594333     Document Type: Article

References (34)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Dávalos A, Toni D, Iweins F, Lesaffre F, Bastianello S, Castillo J. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS) I. Stroke. 1999;30:2631-2636.
4. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. J Am Med Assoc. 2000;283:1145-1150.
5. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley DC, Lewandowski CA, Kwiatkowski TP, for the NINDS rt-PA Stroke Study Group. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55:1649-1655.
6. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet. 2000;355: 1670-1674.
7. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, Levine SR; The Multicentre tPA Stroke Survey Group. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57:474-480.
8. Labiche LA, Al-Senani F, Wojner AW, Grotta JC, Malkoff M, Alex-androv AV. Is the benefit of early recanalization sustained at 3 months? a prospective cohort study. Stroke. 2003;34:695-698.
9. Hacke W, Donnan GA, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley Jr. EC, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
10. Molina CA, Montanar J, Arenillas JF, Ribo M, Rubiera M, Alvarez-Sabin J. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke. 2004;35:486-490.
11. Mori E, Minamatsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T; for the J-ACT II Group. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke. 2010;41:461-465.
12. Del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
13. Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T. Combined intravenous and intra-arterial rt-PA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999;30:2598-2605.
14. Linfante I, Llinas RH, Selim M, Chaves C, Kumar S, Parker RA, Caplan LR, Schlaug G. Clinical and vascular outcome in internal carotid artery vs middle cerebral artery occlusions after intravenous tissue plasminogen activator. Stroke. 2002;33:2066-2071.
15. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, Akhtar N, Orouk FO, Salam A, Shuaib A, Alexandrov AV; for CLOTBUST Investigators. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007;38:948-954.
16. Rother J, Schellinger PD, Gass A, Siebler M, Villringer A, Fiebach JB, Fiehler J, Jansen O, Kucinski T, Schoder V, Szabo K, Junge-Hulsing GJ, Hennerici M, Zeumer H, Sartor K, Weiller C, Hacke W; for the Kompe-tenznetzwerk Schlaganfall Study Group. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke
17. Nakashima T, Toyoda K, Koga M, Matsuoka H, Nagatsuka K, Takada T, Naritomi H, Minematsu K. Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischaemic stroke. Int J Stroke. 2009;4:425-431.
18. De Silva DA, Brekenfeld C, Ebinger M, Christensen S, Barber PA, Butcher KS, Levi CR, Parsons MW, Bladin CF, Donnan GA, Davis SM; for the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) Investigators. The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Stroke. 2010;41:295-299.
19. Kim YS, Garami Z, Mikulik R, Molina CA, Alexandrov AV. Early recanalization rates and clinical outcomes in patients with tandem internal carotid artery/middle cerebral artery occlusion and isolated middle cerebral artery occlusion. Stroke. 2005;36:869-871.
20. Marks MP, Olivot JM, Kemp S, Lansberg MG, Bammer R, Wechsler LR, Albers GW, Thijs V. Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study. Radiology. 2008;249:614-623.
21. Rubiera M, Ribo M, Delgado-Mederos R, Santamarina E, Delgado P, Montaner J, Alvarez-Sabín J, Molina CA. Tandem internal carotid artery/ middle cerebral artery occlusion: an independent predictor of poor outcome after systemic thrombolysis. Stroke. 2006;37:2301-2305.
22. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38:2438-2445.
23. Marder VJ, Chute DJ, Starkman S, Abolian AM, Kidwell C, Liebeskind D, Ovbiagele B, Vinuela F, Duckwiler G, Jahan R, Vespa PM, Selco S, Rajajee V, Kim D, Sanossian N, Saver JL. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke. 2006;37:2086-2093. (Pubitemid 44309909)
24. Blinc A, Francis CW. Transport processes in fibrinolysis and fibrinolytic therapy. Thromb Haemost. 1996;76:481-491.
25. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A. Intravenous recombinant tissue plasmino-gen activator in acute carotid artery territory stroke. Neurology. 1992;42: 976-982.
26. von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke. 1992;23:646-652.
27. Yamaguchi T, Hayakawa T, Kiuchi H. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis. 1993;3:269-272.
28. Yamaguchi T, Kikuchi H, Hayakawa T. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dose-comparison study of duteplase. In: Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ, eds. Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer-Verlag; 1995: 223-229.
29. Chalela JA, Kang DW, Luby M, Ezzeddine M, Latour LL, Todd JW, Dunn B, Warach S. Early MRI findings in patients receiving tissue plasminogen activator predict outcome: insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol. 2004;55:105-112.
30. Kharitonova T, Thorén M, Ahmed N, Wardlaw JM, von Kummer R, Thomassen L, Wahlgren N, for the SITS investigators. Disappearing hyperdense middle cerebral artery sign in ischaemic stroke patients treated with intravenous thrombolysis: clinical course and prognostic significance. J Neurol Neurosurg Psychiatry. 2009;80:273-278.
31. Hirano T, Yonehara T, Inatomi Y, Hashimoto Y, Uchino M. Presence of early ischemic changes on computed tomography depends on severity and the duration of hypoperfusion: a single photon emission-computed tomo-graphic study. Stroke. 2005;36:2601-2608.
32. Hill MD, Rawley HA, Adler F, Eliasziw M, Furlan A, Higashida RT, Wechsler LR, Roberts HC, Dillon WP, Fischbein NJ, Fieszt CM, Schulz GA, Buchan AM. Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. Stroke. 2003;34:1925-1931.
33. Miteff F, Levi CR, Bateman GA, Spratt N, McElduff P, Parsons MW. The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke. Brain. 2009;132:2231-2238.
34. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37: 1810-1815.